Wall Street Zen Downgrades Zimmer Biomet (NYSE:ZBH) to Hold

Key Points

• Wall Street Zen downgraded Zimmer Biomet to “Hold” from “Buy,” while the broader analyst consensus is also “Hold,” with 13 holds, three sells, seven buys/strong buys, and an average price target of $103.53.
• Zimmer Biomet reported quarterly EPS of $2.07, beating estimates by $0.06, while revenue reached $2.18 billion, 4.8% higher year over year and above consensus.
• ZBH shares opened at $96.54, compared with a 52-week range of $79.12 to $108.29; institutional investors and hedge funds own approximately 88.89% of the company.

Zimmer Biomet (NYSE:ZBH - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Saturday.

A number of other brokerages also recently commented on ZBH. Zacks Research downgraded shares of Zimmer Biomet from a "hold" rating to a "strong sell" rating in a research report on Monday, July 27th. UBS Group reiterated a "buy" rating and issued a $120.00 target price on shares of Zimmer Biomet in a research report on Thursday. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Wednesday. Royal Bank Of Canada boosted their price target on shares of Zimmer Biomet from $101.00 to $110.00 and gave the company an "outperform" rating in a report on Thursday. Finally, Canaccord Genuity Group set a $83.00 price target on shares of Zimmer Biomet in a research note on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of "Hold" and an average price target of $103.53.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $96.54 on Friday. The company has a market capitalization of $18.68 billion, a price-to-earnings ratio of 23.49, a P/E/G ratio of 2.85 and a beta of 0.45. Zimmer Biomet has a 1-year low of $79.12 and a 1-year high of $108.29. The company has a current ratio of 1.69, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The stock's fifty day simple moving average is $90.17 and its 200-day simple moving average is $90.13.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business's revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the prior year, the business earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts predict that Zimmer Biomet will post 8.53 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Sang Yi sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider owned 27,251 shares of the company's stock, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.28% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ZBH. DV Equities LLC acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at $25,000. Monetary Solutions Ltd acquired a new position in Zimmer Biomet during the fourth quarter worth $30,000. Gen Wealth Partners Inc bought a new position in Zimmer Biomet during the fourth quarter valued at about $31,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth about $32,000. Finally, Elevation Wealth Partners LLC lifted its position in shares of Zimmer Biomet by 145.9% in the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider's stock worth $33,000 after buying an additional 229 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

About Zimmer Biomet

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source